Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives

Результат исследований: Научные публикации в периодических изданияхстатьярецензирование

3 Цитирования (Scopus)

Аннотация

Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs
Язык оригиналаанглийский
Номер статьи1337
ЖурналPharmaceutics
Том13
Номер выпуска9
СостояниеОпубликовано - 2021

Fingerprint

Подробные сведения о темах исследования «Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives». Вместе они формируют уникальный семантический отпечаток (fingerprint).

Цитировать